Takafumi Ando

572 citations
14 papers · 492 indexed · h-index 10
Topics
NF-κB Signaling Pathways (6 papers)Immune Response and Inflammation (5 papers)Cytokine Signaling Pathways and Interactions (3 papers)

In The Last Decade

Takafumi Ando

14 papers receiving 478 citations

Peers

Takafumi Ando
Comparison fields: 5 of 82
  • Molecular Biology 226
  • Pharmacology 148
  • Immunology 102
  • Cancer Research 101
  • Oncology 65
Replace Biaoyan Du with:
Biaoyan Du China
Zhijie Zhu China
Kanamata Reddy United States
Yanna Jiao China
Jeong-Hyung Lee South Korea
Ming‐Tsung Lai Taiwan
Fenggen Yan China
Wei‐Heng Xu China
Jing Ying Wang China
Dongliang Wang China
Takafumi Ando relative to Biaoyan Du China Biaoyan Du's profile →
Citations per field
00.5×10×17×
Biaoyan Du · 1×
Citations per year

Countries citing papers authored by Takafumi Ando

Since Specialization
Citations

This map shows the geographic impact of Takafumi Ando's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takafumi Ando with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takafumi Ando more than expected).

Fields of papers citing papers by Takafumi Ando

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takafumi Ando. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takafumi Ando. The network helps show where Takafumi Ando may publish in the future.

Co-authorship network of co-authors of Takafumi Ando

This figure shows the co-authorship network connecting the top 25 collaborators of Takafumi Ando. A scholar is included among the top collaborators of Takafumi Ando based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takafumi Ando. Takafumi Ando is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

14 of 14 papers shown
#WorkIndexed citations
1 9
2
Geranylgeranylacetone attenuates cisplatin-induced reductions in cell viability by suppressing the elevation of intracellular p53 content without heat shock protein induction.
6
3 23
4 19
5 13
6 38
7 111
8 25
9 9
10 36
11 41
12 71
13 88
14 3

About Takafumi Ando

Takafumi Ando is a scholar working on Cancer Research, Pharmacology and Immunology, having authored 14 papers that have together received 492 indexed citations. Recurring topics across this work include NF-κB Signaling Pathways (6 papers), Immune Response and Inflammation (5 papers) and Cytokine Signaling Pathways and Interactions (3 papers). The work is most often cited by research in Pharmacology (148 citations), Cancer Research (101 citations) and Complementary and alternative medicine (53 citations). Takafumi Ando has collaborated with scholars based in Japan, United States and Australia. Frequent co-authors include Hidemi Goto, Kazuhiro Ishiguro, Osamu Maeda, Yasumasa Niwa, Naoki Ohmiya, Ramnik J. Xavier, Kenji Kadomatsu, Osamu Watanabe, Aimee Landry and Zhifang Cao. Their work appears in journals such as The Journal of Immunology, Molecular and Cellular Biology and Biochemical and Biophysical Research Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026